Clients trust their most important studies to The Modellers because they are confident that in everything we do, our goal is to provide the best results for better decision-making intelligence.
"The Modellers' IDT is the best simulation tool I have ever used. It does a wonderful job of making a complex model useful. It's both intuitive and robust, plus it's easy to copy and paste everything."
— Market Research Manager, Ortho-McNeil Pharmaceutical
"The Modellers put in the extra effort to really think through their Segmentation Studies to provide the direction we need to hone in on targets... I would use them for every segmentation study...If you're looking for high-end analytics, a true consultant partner, and outputs that are easily translated to your business, then I highly recommend working with this group!"
— Senior Researcher, Johnson & Johnson
"The Modellers provide us with the advanced analytics and in-depth exploration that brings value to our business."
— Executive Director, Interpret, LLC
— GAP, Inc.
"The Modellers take their mission to bridge the gap between academia and industry seriously. They think about problems conceptually, facilitate the academic study of critical issues, and translate acquired knowledge into concrete deliverables. My work with them addresses real marketing problems, and has lead to research published in top academic journals. It is a pleasure for me to be associated with them."
— Greg Allenby, Ohio State University
"The Modellers are excellent at taking a complex set of pricing research objectives and ensuring that the research is rock solid from a methodology perspective and the results are easily digestible for our decision-makers. That's why we've used The Modellers for the past 4 years for our pricing research."
— Executive Director, Symantec
"The Modellers have become a 'go to' resource for our team. On each and every project, The Modellers have taken the time to understand the market, the team, and the business questions well enough to make sure nothing slips through the cracks."
— Senior Researcher, Fortune 500 Pharmaceutical Company